Navigation Links
Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer
Date:6/4/2010

WOODCLIFF LAKE, N.J., June 4 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced the resignation of Lawrence A. Kenyon, executive vice president and chief financial officer, effective June 30, 2010, to pursue other opportunities.  Michael A. Tropiano, Par's Treasurer, will replace Mr. Kenyon.

Mr. Tropiano, 52, joined Par in August 2005 as Vice President and Treasurer.  During his tenure, Mr. Tropiano has led several initiatives including building a Financial, Planning and Analysis team, developing the Company's three-year strategic plan, as well the early redemption of the Company's convertible debentures.  Prior to joining Par, Mr. Tropiano served as Vice President and Corporate Treasurer of MedPointe Pharmaceuticals from 2001-2005 and Assistant Treasurer at Carter–Wallace, Inc. from 1984-2001.  He began his career as a treasury analyst at Orange and Rockland Utilities.  Mr. Tropiano received his Masters of Business Administration in Finance from Fordham University and a Bachelors of Arts in Economics from Siena College.  He is also a Chartered Financial Consultant.

About Par Pharmaceutical

Par Pharmaceutical Companies, Inc. is a U.S.-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.  For press release and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein.  Risk factors that might affect such  forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions.  Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
2. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
3. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
4. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
5. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
6. Jazz Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
7. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
8. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
9. China Yongxin Pharmaceuticals Announces 1-for-12 Reverse Stock Split
10. Thomson CompuMark Launches Worlds Most Comprehensive Trademark Search Offering for Pharmaceutical Brand Owners
11. ISTA Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/19/2017)... April 19, 2017  SARES•REGIS Group leased the ... developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company developing ... diseases that have been underserved by scientific innovation, ... for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... -- Viverae ® , a leader in workplace wellness ... ® Watson Campaign Automation, implementing behavioral messaging within ... personalized experience. Through digital engagement, the platform prompts members ... time. The enhanced experience drives engagement by focusing on ... are in their journey to health. ...
Breaking Medicine Technology:
(Date:4/24/2017)... WA (PRWEB) , ... April 24, 2017 , ... ... leading lifestyle brands, work wear distributors and International relief organizations across the globe ... The company also offers lifestyle and work wear collections via insectshield.com . ...
(Date:4/22/2017)... ... April 22, 2017 , ... Ecommerce sales have grown ... estimated to be $394.9 billion. The consequences of rapid innovation and growth are ... limits of technology, it is every business and individual’s job to give something back ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article in ... teeth, which reveal a great deal about prehistoric ice-age dental practitioners and their primitive ... been used to remove decayed dental matter, and that teeth were then filled with ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... and young adults, has kicked off its 4th annual Forum for Innovative Treatment ... theme is “Attachment Informed Therapy for Mental Health and Addiction.” , FITS’ ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
Breaking Medicine News(10 mins):